+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating whether olomorasib combined with immunotherapy is more effective than standard immunotherapy alone for people with KRAS G12C-mutant non-small cell lung cancer NSCLC. The study has two parts Part A focuses on participants with resected NSCLC treated with pembrolizumab, and Part B includes participants with unresectable NSCLC treated with durvalumab. This Phase 3 study aims to assess disease control and survival outcomes over several years. Participants will be randomly assigned to receive either olomorasib or a placebo, both given orally, combined with intravenous pembrolizumab or durvalumab depending on the study part. Treatment with the combination lasts for up to 1 year, followed by olomorasib or placebo alone for up to 3 years. The study involves parallel groups comparing these combinations in participants with either resected or unresectable disease. During the study, participants will have regular assessments including disease monitoring for progression or recurrence, quality of life questionnaires, and evaluations of lung cancer symptoms. Researchers will track outcomes such as disease-free survival in Part A and progression-free survival in Part B, along with overall survival and symptom changes. The total participation may last about 3 years, with ongoing follow-up to monitor safety and treatment effects.

Age: 18Years +All GendersPhase 3
368 locations